Results 251 to 260 of about 8,279,852 (350)

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Financial hardship among patients with lung cancer and their family caregivers: A comparative study of two institution-based samples from Hong Kong and Mainland China. [PDF]

Asia Pac J Oncol Nurs
Jia S, He J, Ho MH, Cheung DST, Lin CC.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR). [PDF]

Allergy Asthma Immunol Res
Sohn KH, Lee SK, Lee HY, Kim SR, Lee SE, Kim JH, Song WJ, Kim SH, Korean Severe Asthma Registry (KoSAR) Investigators.   +8 more
europepmc   +1 more source

The Postal Life Insurance including dental services in Taiwan during the Japanese colonial period

Journal of Dental Sciences
Feng-Chou Cheng, Ling-Hsia Wang, Chun-Pin Chiang   +2 more
doaj   +1 more source

Effect of Sociodemographic Differences on Elective Lumbar Fusion Surgery. [PDF]

J Am Acad Orthop Surg Glob Res Rev
Lu S, Vander Voort W, Shahzad H, Saade A, Booze Z, Fine J, Ren Y, Zhao A, Harbison G, Roberto R, Klineberg E, Khan S, Le H.   +12 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

From diagnosis to survivorship: Exploring health trajectories of cancer patients in India through a life course perspective. [PDF]

Palliat Care Soc Pract
Sahu S, Kashyap GC, Divakar C, Chattopadhyay S.   +3 more
europepmc   +1 more source

Life Insurance and the Presumption of Death [PDF]

, 1937

core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source